Sandu Pharmaceuticals (524703) Q4 24/25 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended 31 March 2025 were approved, with the subsidiary's results included only up to 10 August 2024 due to divestment.

• Board recommended a final dividend of Rs. 0.80 per equity share (8% of paid-up capital) for FY25, subject to shareholder approval.

• Unmodified audit opinions were issued on both standalone and consolidated financials by the statutory auditors.

Financial highlights

• Standalone revenue from operations for FY25 was Rs. 6,719.24 lakhs, with net profit at Rs. 154.89 lakhs, up from Rs. 146.07 lakhs in FY24.

• Q4 FY25 standalone revenue was Rs. 1,406.92 lakhs, with net profit of Rs. 32.64 lakhs, compared to Rs. 59.24 lakhs in Q4 FY24.

• Consolidated revenue for FY25 was Rs. 6,719.24 lakhs, with net profit at Rs. 155.17 lakhs, compared to Rs. 146.12 lakhs in FY24.

• Total comprehensive income for FY25 stood at Rs. 219.47 lakhs (standalone) and Rs. 219.75 lakhs (consolidated).

Outlook and guidance

• The company will report only standalone results from Q3 FY25 onwards due to the sale and winding up of its subsidiary.

• No large corporate borrowings or debt securities were reported for FY25.